Week in Review: China Pharmas Announce Deals Worth $1.5 Billion

Deals and Financings   WuXi AppTec raised $1 billion in a Hong Kong IPO, which it will use to expand its CRO/CMO operations in China and globally; Shanghai Fosun Pharma in-licensed rights to a Revance next-gen botox candidate for aesthetic and therapeutic use in a $260 million deal; Brii Biosciences, a China-US startup, entered a $128.5 million agreement for China rights to a hepatitis B vaccine immunotherapy from VBI Vaccines of Cambridge, MA; Shenzhen Salubris Pharma announced a $68 million deal for China rights to a treatment for Epstein Barr Virus-associated lymphomas from Viracta of San Diego; Elpiscience, a Shanghai immunoncology company, closed a $35 million Series B round led by Hillhouse Capital for its pipeline of 10 immunotherapy molecules; Germany 's Fresenius Medical, a renal care company, announced several acquisitions that will extend its China network of dialysis clinics; Immunochina, a Beijing biotech, will collaborate with Sartorius Stedim Biotech to develop and manufacture Immunochina's CAR-T therapies; Trials and Approvals   Mundipharma China and Helsinn, a Swiss pharma, announced China approval to market Aloxi® IV, a treatment for chemotherapy-caused nausea and vomiting; Suzhou Innovent Biologics was approved to start US clinical trials of its anti-OX40 immunotherapy in patients with solid tumors; Legend Biotech of Nanjing reported positive data from a China Phase I/II trial of its CAR-T therapy in multiple myeloma patients who failed earlier treatments; CASI Pharma, a US-China company, was granted approval to market Evomela® in China for use as a multiple myeloma treatment; Government and Regulatory   Shanghai held a tendering auction for the rights to supply 31 drugs to Shanghai 's hospital pharmacies; the average price for the drugs dropped 46% and pushed China pharma stock prices sharply lower. Stock Symbols: (SHA: 603259) (SHA: 600196; HK: 2196) (NSDQ: RVNC) (NSDQ: VBIV) (SZE: 002294) (D: FMEG) (HK: 01801) (NSDQ: CASI) Share this with colleagues: // // <br /